Expanding treatment options for thoracic malignancies: Past, Present and Future

14. 1. 2012 - 16. 1. 2012, Hayat Regency, Kuwait

Kongres je podporován ESMO, UICC, AMAAC a IASLC.


Cíle konference:

  • Discuss the heterogeneity of NSCLC and relationship between genetic features of the tumor and clinical course of disease.
  • Asses the influence of histologic types and genetic biomarkers on treatment selection and personalizing regimens in patients with NSCLC .
  • Analyze the role of EGFR expression in selecting treatment for patients with advanced NSCLC
  • Interpret and use the results of molecular and genetic testing to guide treatment selection for patients with NSCLC
  • Identify practice changes that may result in improved clinical outcome and quality of life for patients with NET.
  • Addressing the state of art in management of SCLC, and Mesothelioma.
  • Discussing different diagnostic and therapeutic approaches for common primary mediastinal tumors.


Web: http://lungconferencekuwait.com/

  • Sdílejte na:
    • Facebook
    • Twitter
    • Del.icio.us
    • Digg
    • Google
    • Reddit
    • StumbleUpon
    • Live